Pipeline

August 2, 2021

Company	Drug/Device	Medical Condition	Status
Alzamend Neuro	AL001	dementia related to mild, moderate and severe cognitive impairment associated with Alzheimer’s disease	IND approved by the FDA
Kronos Bio	lanraplenib	relapsed/refractory and newly diagnosed acute myeloid leukemia	IND approved by the FDA
NeoImmuneTech	NT-I7 (efineptakin alfa)	Kaposi sarcoma in patients with or without HIV infection	IND approved by the FDA
I-Mab	efineptakin alfa	advanced solid tumors	IND approved by the Center for Drug Evaluation of the China National Medical Products Administration for a phase 2 trial
Arcturus Therapeutics	ARCT-810	ornithine transcarbamylase deficiency	clinical trial authorized by the UK Health Research Authority
Synchron	Stentrodemotor neuroprosthesis	severe paralysis	Investigational Device Exemption approved by the FDA
Clarity Pharmaceuticals	64/67Cu SAR-bisPSMA theranostic	identification and treatment of metastatic castrate-resistant prostate cancer	initiation of phase 1 trial
Disc Medicine	DISC-0974	anemia of inflammation	initiation of phase 1 trial
Mersana Therapeutics	upifitamab rilsodotin (XMT-1536)	platinum-sensitive ovarian cancer	initiation of phase 1 trial
Karyopharm	XPOVIO in combination with Jakafi	patients with treatment-naïve myelofibrosis	initiation of phase 1/2 trial
MediWound	MW005	low-risk basal-cell carcinoma	initiation of phase 1/2 trial
XyloCor Therapeutics	XC001 (encoberminogene rezmadenovec)	refractory angina	initiation of phase 2 portion of phase 1/2 trial
HutchMed AstraZeneca	Orpathys (savolitinib)	advanced or metastatic MET-amplified gastric cancer or adenocarcinoma of the gastroesophageal junction	initiation of phase 2 trial
Karyopharm	XPOVIO in combination with Keytruda	locally advanced or metastatic melanoma that is resistant to initial checkpoint inhibitor therapy	initiation of phase 2 trial
AbbVie	Dalvance (dalbavancin)	acute bacterial skin and skin structure infections in pediatric patients from birth	approved by the FDA for expanded indication
AstraZeneca	Bydureon BCise (exenatide extended-release)	type 2 diabetes in children 10 years of age and older	approved by the FDA for expanded indication
Merck	Keytruda	high-risk early-stage triple-negative breast cancer	approved by the FDA for new indication
BeiGene	Brukinsa (zanubrutinib)	mantle-cell lymphoma	approved in Canada